STOCK TITAN

Alpha Tau Announces Third Quarter 2026 Financial Results and Provides Corporate Update

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags

Alpha Tau Medical (DRTS) reported third-quarter 2026 results and new interim findings from its Alpha DaRT trial in recurrent glioblastoma. For the nine months ended September 30, net loss widened to $98.9 million from $30.5 million a year earlier, mainly due to higher net financial expenses. Cash and deposits rose to $99.8 million from $76.9 million at year-end 2025.

In REGAIN, all eight treated patients were alive at the interim cutoff; median overall survival had not been reached. All six evaluable patients responded, including five complete responses, at a median follow-up of 6.9 months. The FDA approved expanding REGAIN from 10 to up to 20 patients. Alpha Tau completed IMPACT pancreatic cancer trial enrollment at 48 patients and joined the TA-90 and TA-125 indices after dual-listing in Tel Aviv. The company targets clinical trial supply from the first stage of its Hudson plant by year-end 2026.

Loading...
Loading translation...
22 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 10 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointFDA clearance to expand REGAIN raises planned enrollment from 10 to up to 20 patients across three U.S. centers
  • Moderate pointCash and deposits rose to $99.8 million at September 30, 2026 from $76.9 million at December 31, 2025
  • Minor pointREGAIN objective response rate was 100% in six evaluable patients at 6.9 months median follow-up, with five complete responses
  • Minor pointREGAIN survival: All eight treated patients were alive at the November 11, 2026 cutoff; median overall survival had not been reached
  • Minor pointREGAIN feasibility was 100%, with all planned Alpha DaRT sources deployed in all eight treated patients
17 minor points
  • Minor pointREGAIN safety: No unanticipated serious adverse events were reported at the interim cutoff
  • Minor pointREGAIN local tumor control: No definitive recurrence within the treated area was reported at the interim cutoff
  • Minor pointIMPACT enrollment closed at 48 patients across 10 centers in the U.S., Canada and Israel after three expansions
  • Minor pointHead and neck cancer response rate was 100% among nine evaluable combination-treatment patients versus a 19% historical pembrolizumab-alone benchmark
  • Minor pointHead and neck cancer median overall survival was 18.2 months versus a 12.3-month historical pembrolizumab-alone benchmark
  • Minor pointHead and neck cancer median progression-free survival was 5.4 months versus a 3.2-month historical pembrolizumab-alone benchmark
  • Minor pointHead and neck cancer study safety: No Alpha DaRT-associated serious adverse events were observed
  • Minor pointHead and neck cancer study stopped after recruiting 11 patients, having exceeded its prespecified success threshold
  • Minor point. Forward-looking: it has not happened yet and may not happen.Hudson plant scale-up targets first-stage readiness for clinical trial supply by the end of 2026
  • Minor point. Forward-looking: it has not happened yet and may not happen.ReSTART pivotal skin cancer trial targets initial headline results in Q1 2027, followed by a potential FDA submission
  • Minor point. Forward-looking: it has not happened yet and may not happen.REGAIN trial targets additional interim results in Q1 2027
  • Minor point. Forward-looking: it has not happened yet and may not happen.IMPACT pancreatic cancer pilot targets initial results in H1 2027
  • Minor pointTel Aviv dual listing added local trading in August 2026 under the same DRTS symbol used on Nasdaq
  • Minor point. Forward-looking: it has not happened yet and may not happen.TA-90 and TA-125 inclusion took effect November 5, 2026, with index-tracking funds expected to add Alpha Tau shares
  • Minor pointADMIRE trial treated its first immunocompromised patient with recurrent cutaneous squamous cell carcinoma
  • Minor point. Forward-looking: it has not happened yet and may not happen.U.S. recurrent prostate cancer pilot targets first patient treatment at year-end 2026
  • Minor pointMarketing expenses fell to $0.9 million from $1.4 million year over year for the nine months ended September 30, 2026

Negative

  • Moderate pointNine-month net loss widened to $98.9 million, or $1.09 per share, from $30.5 million, or $0.39 per share, a year earlier
  • Moderate pointWarrant liability rose to $66.035 million at September 30, 2026 from $5.354 million at December 31, 2025
  • Moderate pointShareholders’ equity fell to $19.647 million at September 30, 2026 from $77.099 million at December 31, 2025
  • Minor pointNine-month net financial expenses rose to $58.5 million from $0.6 million year over year, mainly from revaluing warrant liabilities
  • Minor pointNine-month research and development expenses rose to $31.7 million from $22.5 million year over year
5 minor points
  • Minor pointOrdinary shares outstanding increased to 93,084,841 at September 30, 2026 from 88,009,737 at December 31, 2025
  • Minor pointNine-month general and administrative expenses rose to $7.6 million from $5.8 million year over year
  • Minor pointREGAIN tumor progression outside the treated area occurred in one patient approximately nine months after treatment
  • Minor pointLong-term loan balance rose to $6.615 million at September 30, 2026 from $6.352 million at December 31, 2025
  • Minor pointNine-month income tax expense rose to $216,000 from $156,000 year over year

News Explained

Warrant-liability remeasurement was the primary source of $58.5 million in net financial expenses for the nine months ended September 30, 2026.

Alpha Tau reported third-quarter 2026 results; its issued-and-outstanding ordinary shares were 93,084,841 at September 30, 2026, versus 88,009,737 at December 31, 2025. For holders who kept the same number of shares, the higher total reduces their fraction of the company relative to year-end 2025.

For the nine months ended September 30, 2026, net financial expenses were $58.5 million, primarily due to remeasurement of warrant liability as the public trading prices of ordinary shares and publicly traded warrants rose. The balance sheet listed warrant liability at $66,035 thousand on September 30, 2026.

Key Figures

Objective response rate: 100% Complete responses: 5 of 6 (83.3%) Survival status: All 8 treated patients alive; median overall survival not reached +5 more
Objective response rate
100%
First 6 evaluable REGAIN patients
Complete responses
5 of 6 (83.3%)
REGAIN patients who reached response assessment
Survival status
All 8 treated patients alive; median overall survival not reached
As of the November 11, 2026 data cut-off
Median follow-up
6.9 months
Six patients who reached response assessment
REGAIN trial enrollment expansion
From 10 to up to 20 patients
FDA-approved trial expansion
Feasibility
100%
Planned Alpha DaRT sources deployed in all 8 treated patients
Net loss
$98.9 million
Nine months ended September 30, 2026; compared with $30.5 million in 2025
Cash, deposits and restricted deposits
$99.8 million
September 30, 2026; compared with $76.9 million at December 31, 2025

Previous Earnings Reports

1 past event · Latest: Aug 10
Same Type 1 event
  1. Aug 10

    Quarterly results

    24h Move
    +4.9%

    Earlier REGAIN update reported 100% local disease control and 67% complete response.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

objective response rate, median overall survival, investigational device exemption, progression-free survival, +1 more
5 terms
objective response rate medical
"100% objective response rate, including five complete responses"
The objective response rate (ORR) is the percentage of patients in a clinical trial whose tumors measurably shrink or disappear according to preset rules. Investors use it as a quick, objective signal of a drug’s ability to produce a clear treatment effect—like counting how many plants visibly respond after applying a new fertilizer—and higher ORR can improve odds of regulatory approval, commercial success, and company valuation.
median overall survival medical
"median overall survival had not been reached"
Median overall survival is the middle point of how long patients live after starting treatment, meaning half live longer and half live shorter. It helps doctors understand how effective a treatment is and gives patients an idea of what to expect about their future.
investigational device exemption regulatory
"Investigational Device Exemption (IDE) supplement expanding REGAIN"
An investigational device exemption (IDE) is a regulatory permission that allows a medical device maker to test an unapproved device in people so the device’s safety and effectiveness can be studied. For investors, an IDE matters because it marks a formal step toward regulatory approval—like getting a temporary test-drive permit—and influences clinical cost, timelines, and the likelihood a device will reach the market and generate revenue.
progression-free survival medical
"adding progression-free survival as a secondary endpoint"
Progression-free survival is the length of time during and after a treatment that a patient's disease does not get worse, measured from the start of treatment until the disease shows measurable signs of progression or the patient dies. Investors care because longer progression-free survival in clinical trials often signals that a drug is effective, improving chances of regulatory approval, market adoption, and revenue potential—think of it as a stopwatch showing how long a therapy can keep the illness at bay.
mfolfirinox medical
"either mFOLFIRINOX or gemcitabine with Abraxane"
mFOLFIRINOX is a modified chemotherapy combination of several drugs given together to treat certain cancers; think of it as a tailored cocktail of medicines intended to attack tumors more effectively than a single drug. It matters to investors because clinical trial results, safety and approval of this regimen can change a drugmaker’s revenue outlook and influence hospital treatment choices, so positive or negative outcomes often move stock prices and valuation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

- New interim results from the U.S. REGAIN recurrent glioblastoma trial presented at the SNO 2026 Annual Meeting: all eight treated patients alive, with median overall survival not reached, and a 100% objective response rate, including five complete responses, in the first six evaluable patients at 6.9 months median follow-up, with 100% feasibility and no unanticipated serious adverse events -

- FDA approval to expand the REGAIN trial from 10 to up to 20 patients, which the Company believes could generate data that may support market submission requirements for Alpha DaRT® in recurrent glioblastoma -

- Completion of patient enrollment in the multicenter IMPACT pancreatic cancer pilot study, with 48 patients enrolled across 10 clinical centers in the U.S., Canada and Israel following strong demand and three trial expansions -

- Dual listing on the Tel Aviv Stock Exchange (TASE), followed by inclusion in the flagship TA-90 and TA-125 indices -

- Meaningful additional data anticipated from multiple trials in the coming months -

- Ongoing manufacturing scale-up, with the first stage of the Company’s Hudson, New Hampshire plant targeted to be ready for clinical trial supply by the end of 2026 -

- Cash, cash equivalents, short-term deposits and restricted deposits balance of $99.8 million provides runway for continued clinical advancement and commercial preparation -

JERUSALEM, Nov. 19, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ / TASE: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, reported third quarter 2026 financial results and provided a corporate update.

“Alpha Tau has tremendous momentum right now, and the new fantastic interim data from our REGAIN trial in recurrent glioblastoma showcase the true power of Alpha DaRT,” said Alpha Tau CEO Uzi Sofer. “While the trial started with a focus on feasibility and safety, we initially begin to see responses to the treatment, and are now seeing this translate into patient survival. We will continue to follow these patients closely as their scans mature, but we believe they speak to what a potent, highly localized alpha-emitting therapy may be able to do in even the hardest-to-treat tumors. With the FDA having approved the expansion of REGAIN to up to 20 patients, which we believe may support market submission requirements for Alpha DaRT, we are pressing ahead with enrollment, while preparing for mass production and commercialization if and when we are able to secure such an authorization.”

“The glioblastoma data reflect only one part of Alpha Tau’s much broader opportunity to meaningfully change how cancer is treated,” continued Mr. Sofer. “In recent months we completed enrollment of 48 patients in our multicenter IMPACT pancreatic cancer pilot study, after three expansions driven by strong demand, and treated the first immunocompromised patient in our ADMIRE study. We now expect meaningful additional data from multiple trials in the coming months, including top-line data from our pivotal ReSTART trial in recurrent cSCC, initial data from IMPACT, and additional interim data from REGAIN.”

“To be ready for the demand that we believe these data can generate, we continue to scale up our manufacturing capabilities. A central piece of that effort is bringing the first stage of our Hudson, New Hampshire plant online, which we are targeting to be ready for clinical trial supply by the end of 2026.”

“On the corporate front, we are very pleased to have come home to Israel with our dual listing on the Tel Aviv Stock Exchange, quickly followed by our inclusion in the flagship TA-90 and TA-125 indices. With a strong balance sheet of $99.8 million, a growing body of clinical evidence across multiple tumor types, and a dense calendar of data readouts ahead of us, we believe Alpha Tau has never been better positioned to translate this momentum into meaningful impact for patients.”

Recent Corporate Highlights:

  • In November 2026, Alpha Tau announced new interim results from its U.S. REGAIN (Recurrent Glioblastoma Alpha DaRT Intratumoral Therapy) trial of Alpha DaRT in recurrent glioblastoma (GBM), presented at the 31st Annual Meeting of the Society for Neuro-Oncology (SNO) in Philadelphia by the study investigator team from The Ohio State University Comprehensive Cancer Center. As of the November 11, 2026 data cut-off, all eight patients treated in the trial were alive and median overall survival had not been reached, with a median follow-up of 6.9 months from trial enrollment (range 3.1 to 11.6 months) in the six patients who had reached response assessment. All six of these patients (100%) achieved an objective response as their best overall response under RANO criteria, comprising five complete responses (83.3%) and one partial response (16.7%) with a 58% decrease in tumor measurements. On the trial’s primary endpoints of feasibility and safety, all planned Alpha DaRT sources were successfully deployed in all eight patients (100%), with no unanticipated serious adverse events. No definitive recurrence within the treated area has been reported in any patient, although one patient developed tumor progression away from the treated area approximately nine months after treatment. The results follow the FDA’s approval in October 2026 of an Investigational Device Exemption (IDE) supplement expanding REGAIN from 10 to up to 20 patients across three U.S. academic cancer centers and adding progression-free survival as a secondary endpoint, regular quality-of-life assessments and an additional interim analysis. The Company believes that the expanded trial could generate data that may support market submission requirements for Alpha DaRT in recurrent GBM. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06910306
  • In October 2026, Alpha Tau announced the inclusion of its ordinary shares in the flagship TA-90 and TA-125 indices of the Tel Aviv Stock Exchange (TASE), effective November 5, 2026, making Alpha Tau one of three biomed companies in the TA-125, with funds tracking these indices expected to add Alpha Tau shares to their holdings. The index inclusion follows the Company’s dual listing on the TASE in August 2026, which was undertaken in light of growing interest from Israeli investors and requests from the local investor base to trade the Company’s shares in local currency and during local business hours. The Company’s ordinary shares now trade on both Nasdaq and the TASE under the symbol DRTS.
  • In August 2026, Alpha Tau announced the completion of patient enrollment in its multicenter IMPACT (Intratumoral Pancreatic Alpha Combination Trial) pilot study of Alpha DaRT in pancreatic cancer, with 48 patients enrolled across 10 clinical centers in the United States, Canada and Israel. Originally approved for 12 patients, the study was expanded three times following strong demand, with the third expansion requested by participating clinical sites and broadening eligibility to multiple disease stages and both first-line chemotherapy regimens. IMPACT evaluates a one-time intratumoral Alpha DaRT treatment, delivered under real-time endoscopic ultrasound (EUS) guidance, as an add-on to first-line chemotherapy with either mFOLFIRINOX or gemcitabine with Abraxane® (nab-paclitaxel), in patients with newly diagnosed, unresectable locally advanced or metastatic pancreatic adenocarcinoma. For more information, please see here: https://www.clinicaltrials.gov/study/NCT06698458
  • In July 2026, Alpha Tau reported positive results from a clinical study evaluating Alpha DaRT in combination with pembrolizumab (Keytruda®) in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma (HNSCC), delivered in a podium presentation at the American Head and Neck Society (AHNS) 12th International Conference on Head and Neck Cancer in Boston. Among all nine evaluable patients, the combination produced a systemic objective response rate of 100%, including four complete responses and five partial responses, compared to just 19% from historical benchmarks for pembrolizumab monotherapy in this setting. Median overall survival of 18.2 months and median progression-free survival of 5.4 months compared favorably with historical benchmarks for pembrolizumab monotherapy of 12.3 months and 3.2 months, respectively. No Alpha DaRT-associated serious adverse events were observed, and the study was stopped after the recruitment of 11 patients, having surpassed its pre-specified threshold for success.
  • In July 2026, Alpha Tau announced the successful treatment of the first patient in its ADMIRE (Alpha DaRT Management for Immunocompromised patients with recurrent cSCC) study, a clinical trial evaluating intratumoral Alpha DaRT in immunocompromised patients with recurrent cutaneous squamous cell carcinoma (cSCC), performed at Banner MD Anderson Cancer Center in Gilbert, Arizona. Immunosuppression is one of the strongest known risk factors for cSCC, and these patients are frequently excluded from clinical trials and often cannot safely receive checkpoint inhibitor immunotherapy. The prospective, multicenter, open-label, single-arm study is designed to enroll up to 28 patients at up to eight U.S. sites. For more information, please see here: https://clinicaltrials.gov/study/NCT06615635

Expected Upcoming Milestone Targets:

Financial Results for the Nine Months Ended September 30, 2026
Research and Development expenses for the nine months ended September 30, 2026 were $31.7 million, compared to $22.5 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, increased clinical trial activity and payments to subcontractors, and increased raw material purchases.

Marketing expenses for the nine months ended September 30, 2026 were $0.9 million, compared to $1.4 million for the same period in 2025, primarily due to decreased employee compensation and benefits.

General and Administrative expenses for the nine months ended September 30, 2026 were $7.6 million, compared to $5.8 million for the same period in 2025, primarily due to increased employee compensation and benefits, including share-based compensation, and higher professional fees.

Financial expenses, net, for the nine months ended September 30, 2026 were $58.5 million, compared to $0.6 million for the same period in 2025, primarily due to the remeasurement of warrants liability, as the public trading prices of the Company’s ordinary shares and publicly traded warrants rose over the period.

For the nine months ended September 30, 2026, the Company had a net loss of $98.9 million, or $1.09 per share, compared to a net loss of $30.5 million, or $0.39 per share, for the nine months ended September 30, 2025.

Balance Sheet Highlights

As of September 30, 2026, the Company had cash and cash equivalents, short-term deposits and restricted deposits of $99.8 million, compared to $76.9 million at December 31, 2025.

About Alpha DaRT

Alpha DaRT® (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, words including “anticipate,” “believe,” “expect,” “will,” “plan,” “may,” “could,” “continue,” “aim,” “goal,” “target,” “potential,” “designed to,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, milestone targets, beliefs, plans, including with respect to clinical trials and planned treatments regulatory approvals and expected responses, studies, patient recruitment, the anticipated timing of data readouts, projections, objectives, performance, our ability to commercialize, our manufacturing facilities and future production, including the timing of readiness of the Hudson, New Hampshire plant, the Company’s financial position and cash runway, the anticipated effects of the Company’s TASE listing and index inclusion, applications with regulatory bodies or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Alpha Tau’s current expectations and various assumptions. Alpha Tau believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Alpha Tau may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation: (i) Alpha Tau’s ability to receive regulatory approval for its Alpha DaRT technology or any future products or product candidates; (ii) Alpha Tau’s limited operating history; (iii) Alpha Tau’s incurrence of significant losses to date; (iv) Alpha Tau’s need for additional funding and ability to raise capital when needed; (v) Alpha Tau’s limited experience in medical device discovery and development; (vi) Alpha Tau’s dependence on the success and commercialization of the Alpha DaRT technology; (vii) the failure of preliminary data from Alpha Tau’s clinical studies to predict final study results; (viii) failure of Alpha Tau’s early clinical studies or preclinical studies to predict future clinical studies; (ix) Alpha Tau’s ability to enroll patients in its clinical trials; (x) undesirable side effects caused by Alpha Tau’s Alpha DaRT technology or any future products or product candidates; (xi) Alpha Tau’s exposure to patent infringement lawsuits; (xii) Alpha Tau’s ability to comply with the extensive regulations applicable to it; (xiii) the ability to meet Nasdaq’s listing standards; (xiv) costs related to being a public company; (xv) changes in applicable laws or regulations; and the other important factors discussed under the caption “Risk Factors” in Alpha Tau’s annual report filed on Form 20-F with the SEC on March 9, 2026, and other filings that Alpha Tau may make with the United States Securities and Exchange Commission. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While Alpha Tau may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing Alpha Tau’s views as of any date subsequent to the date of this press release.

Investor Relations Contact:

IR@alphatau.com

INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands
 
  December 31, September 30,
  2025
 2026
    Unaudited
ASSETS    
     
CURRENT ASSETS:    
Cash and cash equivalents $12,202 $17,025
Short-term deposits  60,924  78,699
Restricted deposits  3,777  4,070
Prepaid expenses and other receivables  1,395  1,781
     
Total current assets  78,298  101,575
     
LONG-TERM ASSETS:    
Long-term prepaid expenses  479  523
Property and equipment, net  19,661  19,191
Operating lease right-of-use assets  7,214  7,667
     
Total long-term assets  27,354  27,381
     
Total assets $105,652 $128,956


INTERIM CONSOLIDATED BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
 
  December 31, September 30,
  2025 2026
    Unaudited
     
LIABILITIES AND SHAREHOLDERS’ EQUITY    
     
CURRENT LIABILITIES:    
Trade payables $3,868 $3,680
Other payables and accrued expenses  5,508  5,726
Current maturities of operating lease liabilities  1,131  1,327
     
Total current liabilities  10,507  10,733
     
LONG-TERM LIABILITIES:    
Long-term loan  6,352  6,615
Warrants liability  5,354  66,035
Operating lease liabilities  6,243  6,738
Deferred revenue  -  18,878
Deferred tax liability  97  310
     
Total long-term liabilities  18,046  98,576
     
Total liabilities  28,553  109,309
     
SHAREHOLDERS' EQUITY:    
Ordinary shares of no-par value per share – Authorized: 362,116,800 shares as of December 31, 2025 and September 30, 2026; Issued and outstanding: 88,009,737 and 93,084,841 shares as of December 31, 2025 and September 30, 2026 respectively  -  -
Additional paid-in capital  267,235  308,689
Accumulated deficit  (190,136)  (289,042)
     
Total shareholders' equity  77,099  19,647
     
Total liabilities and shareholders' equity $105,652 $128,956


INTERIM CONSOLIDATED STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
 
  Nine months ended September 30,
  2025
 2026
  Unaudited
     
Research and development $22,489 $31,686
     
Marketing expenses  1,408  920
     
General and administrative  5,789  7,623
     
Total operating loss  29,686  40,229
     
Financial expenses, net  649  58,461
     
Loss before taxes on income  30,335  98,690
     
Tax on income  156  216
     
Net loss  30,491  98,906
     
Net loss per share, basic and diluted $0.39 $1.09
     
Weighted-average shares used in computing net loss per share, basic and diluted  78,721,389  91,103,211

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Alpha Tau Medical's interim REGAIN glioblastoma results show?

All eight treated patients were alive at the November 11, 2026 cutoff, and all six evaluable patients had an objective response at a median follow-up of 6.9 months. Five had a complete response and one had a partial response. Median overall survival had not been reached.

What drove Alpha Tau Medical's wider net loss in its third-quarter 2026 results?

Higher net financial expenses, mainly from revaluing the warrant liability, were the largest contributor to the wider loss. For the nine months ended September 30, 2026, net financial expenses rose to $58.5 million from $0.6 million a year earlier, and net loss widened to $98.9 million from $30.5 million.

What changed in Alpha Tau Medical's REGAIN trial under the FDA-approved expansion?

The expansion adds a measure of how long patients live without tumor progression as a secondary endpoint, along with regular quality-of-life assessments and another interim analysis. Alpha Tau believes data from the expanded trial may help support a market submission for Alpha DaRT in recurrent glioblastoma.

What is Alpha Tau Medical testing in the IMPACT pancreatic cancer study?

IMPACT is testing a one-time Alpha DaRT treatment added to first-line chemotherapy in patients with newly diagnosed pancreatic adenocarcinoma that cannot be removed surgically and is either locally advanced or metastatic. The treatment is delivered directly into the tumor using real-time endoscopic ultrasound guidance.

When does Alpha Tau Medical expect results from ReSTART, REGAIN and IMPACT?

Alpha Tau targets Q1 2027 for headline ReSTART results and additional interim REGAIN data. It targets H1 2027 for the first IMPACT results. A potential FDA submission could follow the ReSTART readout.

Keep reading